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Avoiding danger and finding food, which are life-sustaining activities that are regulated 
by emotion, reward and energy balance, require proper wakefulness. The orexin system 
regulates sleep and wakefulness through interactions with systems that regulate emotion, 
reward and energy homeostasis. This system regulates sleep and wakefulness to occur at 
appropriate times that are in accordance with our internal and external environments.  
Recent findings have brought about the possibility of novel therapies targeting orexin 
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system for sleep disorder including insomia and narcolepsy-cataplexy. In this review, 
we will discuss the current understanding of the integrative physiology and clinical 





Ascending reticular activating system 
The ascending reticular activating system is a concept originally proposed by Moruzzi 
& Magoun in 1949. They found that stimulation at the core of the reticular formation 
in the brain stem is effective in inducing desynchronization pattern of the EEG in cat, 
suggesting this stimulation cause cortical arousal. Lesion of the reticular formation 
produced chronic EEG inactivation and somnolence. These studies introduced the 
concept that cortical activation was actively maintained by the tonic activation of 
brainstem core neurons. Currently, it is commonly considered that the reticular 
activating system is composed of several ascending pathways including monoaminergic 
and cholinergic neurons in the brain stem. 
 
Narcolepsy 
Neurological condition most characterized by excessive daytime sleepiness, episodes of 
sleep and disorder of REM or rapid eye movement sleep. 
 
Cataplexy 
Episodic condition featuring loss of muscle function, ranging from slight weakness 
(such as limpness at the neck or knees, sagging facial muscles, or inability to speak 
clearly) to complete body collapse. Cataplexy is often observed in narcolepsy patients. 
 
Non-rapid eye movement (NREM) sleep 
Sleep is a cyclic process. Under normal conditions, sleep is characterized by regular 
alternation between rapid eye movement sleep (REM) and non-rapid eye movement 
sleep (NREM). NREM sleep is divided into 4 stages; Stages 1 and 2 are characterized 
by low arousal thresholds and are considered light sleep.  Stages 3 and 4 are 
characterized by high arousal thresholds and are considered deep or “slow wave” sleep. 
All 4 of these stages can be differentiated by electroencephalography (EEG).  Stage 1 is 
marked by low voltage, mixed frequency EEG. Stage 2 is marked by the presence of K 
complexes and sleep spindles on EEG recordings. Both stages 3 and 4 are marked by 
delta waves, which have a voltage of 75 microvolts or more and a frequency range of 0.5 
to 4 hertz, but differ in composition.  Stage 3 is defined as sleep consisting of 20-50% 




Rapid eye movement (REM) sleep 
The stage of sleep characterized by rapid movements of the eyes. It was identified and 
defined by Nathaniel Kleitman and Eugene Aserinsky in 1953. Criteria for REM sleep 
includes low muscle tone and a rapid, low-voltage EEG. REM sleep in adult humans 
typically occupies 20–25% of total sleep, about 90–120 minutes of a night's sleep. 
 
ventrolateral preoptic nucleus (VLPO) 
The ventrolateral preoptic nucleus (VLPO) is a region of the anterior hypothalamus, 
which includes sleep-active neurons, which inhibit the major ascending monoaminergic 
arousal systems during sleep. 
 
Lateral hypothalamic area (LHA) 
The lateral hypothalamus or lateral hypothalamic area is a region of the hypothalamus, 
generally including the lateral hypothalamic area and lateral preoptic nucleus. 
Classically, this region is considered as a feeding center. Stimulation of this area causes 
increased food intake, while bilateral lesion of this area causes cessation of feeding. 
This region receives input from amygdala. This area contains glucose sensitive neurons, 
which are inhibited by glucose This region are also critically involved in the regulation 




Feeding behavior is greatly affected by emotion, reward and energy balance. 
Simultaneously, it requires proper wakefulness and vigilance. Regulatory centers of 
feeding and energy homeostasis are believed to be localized within the hypothalamus, 
whereas the most critical neuronal network for wakefulness is the ascending reticular 
activating system (ARAS) in the brainstem that sends projections to multiple areas of 
the forebrain. These observations suggest the existence of a neuronal system that acts as 
a link between the feeding centers in the hypothalamus and the brainstem "waking 
center". Recent evidence clearly suggests that orexin-producing neurons in the 
hypothalamus are crucial for such linkage.   
 Orexin A and orexin B (also known as hypocretin 1 and hypocretin 2) are 
hypothalamic neuropeptides that were discovered thirteen years ago. Initially, these 
peptides were recognized as regulators of feeding behavior1. Subsequently, several 
studies suggested that orexin deficiency causes narcolepsy in humans and other 
mammalian species, highlighting roles of this hypothalamic neuropeptide in the 
regulation of sleep and wakefulness2. Studies of efferent and afferent systems of orexin-
producing neurons have shown that the orexin neuronal system has close interactions 
with systems that the regulate  emotion, energy homeostasis, reward, and arousal3-10. 
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These observations suggest that orexin neurons are involved in sensing the body’s 
external and internal environments, and regulate vigilance states accordingly. In this 
review, we will discuss the mechanisms by which the orexin system regulates 
wakefulness in relation to energy homeostasis and other systems. We will also discuss 
the therapeutic potential of drugs that target orexin receptors. 
 
Orexin and orexin receptors 
In 1998, our research team identified novel neuropeptides, orexin A and orexin B, from 
rat brain extracts as two endogenous ligands for two orphan G-protein-coupled 
receptors by a method called "reverse pharmacology" 1. Molecular cloning studies 
showed that both orexin A and orexin B are derived from a common precursor peptide, 
prepro-orexin (Figure1). An mRNA encoding the same precursor peptide was 
independently identified by de Lecea et al. as a hypothalamus-specific transcript11.  The 
authors predicted that the transcript encoded a polypeptide precursor that is cleaved to 
form two neuropeptides, termed hypocretin-1 and hypocretin-2 (corresponding to orexin 
A and orexin B, respectively).  Orexin A and orexin B constitute a novel distinct peptide 
family, showing no significant homology with any previously described peptides12.  
Structural analysis of purified peptide showed that orexin A is a 33-amino-acid peptide 
with an N-terminal pyroglutamyl residue, two intra-chain disulfide bonds, and C-
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terminal amidation.  This structure is completely conserved among several mammalian 
species (human, rat, mouse, cow, sheep, dog and pig).  Orexin B is a 28-amino-acid, C-
terminally amidated linear peptide. Amino acid sequences of various species of orexin B 
show that there are several species differences, although highly conserved. The C-
terminal half of orexin B is very similar to that of orexin A, whereas the N-terminal half 
is more variable.  
The actions of orexins are mediated via two G-protein coupled receptors 
(GPCRs), orexin 1 (OXR-1) and orexin 2 (OXR-2) receptors (also known as Hcrtr1 and 
Hcrtr2).  OXR-1 has one-order-of-magnitude greater affinity for orexin A over orexin B.  
In contrast, OXR-2 accepts both ligands with similar affinities1.  OXR-1 couples to Gq/11 
class of G-protein, which results in activation of phospholipase C to trigger of the 
phosphatidylinositol cascade and influx of extracellular Na+ and Ca2+ , presumably 
through TRP channels to cause depolarization of neurons.  OXR-2 couples to both Gq/11 
or Gi-classes of G-proteins in a neuronal cell line13. OXR-1 and OXR-2 mRNAs exhibit 
a markedly different and basically complementary distribution, suggesting that these 
receptors have distinct physiological roles through different neuronal pathways 14.   
Orexin neurons, which have been assumed to number around 3,000 in rat brains, 
or 70,000 in human brains15-16, are localized exclusively in the hypothalamus, including 
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the lateral hypothalamic area (LHA), perifornical area, and posterior hypothalamus (PH) 
15-17.  
 
Implication of orexins in the pathophysiology of narcolepsy 
What is narcolepsy? 
An understanding of narcolepsy, a sleep disorder that results from loss of orexin neurons, 
provides insight into the physiological functions of orexins. Narcolepsy is a debilitating 
neurological disorder that affects approximately 1 in 2000 individuals in the United 
States18.  A cardinal symptom of the disorder is excessive daytime sleepiness (an 
insurmountable urge to sleep), which often results in falling asleep at inappropriate 
times and situations (‘sleep attack’).  The latency for rapid eye movement (REM) sleep 
is notably reduced in narcolepsy patients, and the existence of ‘sleep-onset REM 
periods’ (i.e. REM-sleep is directly preceded by an awake period) is one of the 
diagnostic criteria for narcolepsy.  Nocturnal sleep is often disturbed by sleep 
fragmentation combined with the occurrence of hypnagogic hallucinations, vivid 
dreaming, and sleep paralysis, which usually occur immediately after patients fall asleep.  
Narcolepsy patients often suffer from a condition called “cataplexy”, which is a sudden 
weakening of muscle tone, ranging from jaw dropping and speech slurring to complete 
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bilateral collapse of the postural muscles.  Usually, cataplexy is triggered by emotional 
stimuli. Unlike the sleep attack, consciousness is preserved during cataplexy.  
Narcolepsy with cataplexy is sometimes referred as “narcolepsy-cataplexy”.  
 Thus, narcolepsy is characterized by the inability to maintain wakefulness states, 
pathological intrusion of REM sleep into wakefulness, and frequent transitions between 
states of sleep and wakefulness, which suggests that orexins have important roles in the 
maintenance and stabilization of sleep and wakefulness and REM sleep regulation. 
Roles of orexins in pathophysiology of narcolepsy 
The first clues that orexins are involved in narcolepsy came from animal models. Mice 
lacking the orexin gene or dogs with null mutations in OXR-2 show phenotypes 
remarkably similar to human narcoleptic patients19-20.  Prepro-orexin knockout (KO) 
mice, orexin neuron-ablated (orexin/ataxin-3-transgenic) mice, and OXR-1/OXR-2 
double KO mice show similar phenotypes that have strong parallels to the human 
condition, characterized by behavioral arrests that are similar to cataplexy, occasional 
direct transitions to REM sleep from wakefulness, and highly fragmented sleep-wake 
cycles 19, 21, all of which are important elements of narcolepsy. 
The link between orexin dysfunction and narcolepsy (especially if narcolepsy-
cataplexy) has since been supported by studies with human patients.  A postmortem 
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study of human narcolepsy subjects showed no detectable levels of orexin peptides in 
the cortex and pons, in which normally orexinergic projections are found (Figure 2A), 
and an 80-100% reduction in the number of neurons containing detectable prepro-orexin 
mRNA or orexin-like immunoreactivity in the hypothalamus22-23.  Approximately 90% 
of patients with narcolepsy are shown to have decreased orexin A levels in the 
cerebrospinal fluid24.  Therefore, a low CSF level of orexin A (less than 110 pg/ml) is 
now one of the diagnostic criteria for narcolepsy-cataplexy according to the 2nd edition 
of the international classification of sleep disorders25.  
Because of its strong association with certain human leukocyte antigen(HLA) 
alleles26, it has been speculated that narcolepsy results from selective immune-mediated 
degeneration of orexin neurons. Recently, Tribbles homolog 2 (Trib2) was reported as a 
possible antigen involved in the autoimmune destruction of orexin neurons27.  Trib2 was 
abundantly expressed in orexin neurons, and levels of Trib2-specific antibodies were 
much greater in people with narcolepsy.  Recent studies also reported that susceptibility 
to narcolepsy is associated with single nucleotide polymorphysms (SNPs) in the T-cell 
receptor alpha locus28 and those located between the carnitine palmitoyl- transferase 1B 
and choline kinase beta29.  
Regardless of the cause of the neuronal loss, the orexin signaling deficiency in 
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narcolepsy-cataplexy shows that this neuropeptide system plays an important role in the 
regulation of sleep and wakefulness, especially in the maintenance of long, consolidated 
awake periods.  
Pathological Contribution of Each Receptor Subtype 
 Narcolepsy can be divided into two pathological phenomena, suggesting that 
pathophysiology of narcolepsy is caused by two independent mechanisms.  One is a 
difficulty in maintaining long awake periods, characterized by abrupt transitions from 
wakefulness to NREM sleep (dysregulation of NREM sleep onset). This phenomenon 
manifests clinically as excessive daytime sleepiness, which sometimes results in sleep 
attacks. Mouse studies suggested that it largely results from a lack of OXR-2 signaling30. 
Psychostimulant drugs, such as modafinil, methyl phenidate, amphetamine and caffeine 
are used to treat these symptoms. 
 The other key phenomenon is the pathological intrusions of REM sleep into 
wakefulness (dysregulation of REM sleep onset); it is during these periods that the 
patient might experience cataplexy, hypnagogic hallucinations, sleep paralysis.  
Available therapy for this symptom consists of tricyclic antidepressants such as 
imipramine and serotonin-specific reuptake inhibitors (SSRIs)31, suggesting existence of 
abnormal monoaminergic neurotransmission in cataplexy.  Lack of signaling from both 
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receptors is critically associated with this symptom32-33. 
Input to orexin neurons 
Recent studies using anterograde and retrograde tracers suggest that orexin neurons 
receive abundant projections from the lateral septum, the preoptic area, the amygdala, 
the bed nucleus of the stria terminalis (BNST), the posterior/dorsomedial hypothalamus, 
and the serotonergic neurons in the raphe nuclei7-8.  
Input from limbic system 
Abundant input from the limbic system7-8, 34 (which is implicated in emotion) suggests it 
plays a part in the regulation of the firing rate of orexin neurons. Indeed, the importance 
of this connection is apparent in the defense (or "fight or flight") response. Mice tested 
in a resident-intruder paradigm show cardiovascular and locomotor responses to 
emotional stress, but these responses are diminished in prepro-orexin KO mice 35. 
Similarly, air-jet stress-induced elevations of blood pressure and heart rate were 
attenuated in conscious orexin/ataxin-3 transgenic mice, in which orexin neurons are 
genetically ablated36. Furthermore, in urethane-anesthetized mice, microinjection of the 
GABAA receptor antagonist bicuculline into the amygdala or BNST increased Fos 
immunoreactivity in orexin neurons and induced long-lasting and dose-dependent 
cardiorespiratory excitation in wild-type mice. By constrast, in orexin-ataxin 3 mice, 
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cardiorespiratory responses after disinhibition of the amygdala were not observed and 
those after activation of the BNST were attenuated. These observations suggest that 
orexin-containing neurons mediate at least a part of amygdala- and BNST-induced 
increases in the sympathetic outflow37. 
The lower level of activation of the sympathetic out flow by emotional stimuli, 
might affect the establishment of emotional memory, because emotional reaction has 
been known to be strongly affected by sympathetic responses. Abnormality of amygdala 
function was recently reported in human narcolepsy patients, using functional MRI 
(fMRI) imaging38. The study reported no enhancement of amygdala response to 
conditioned stimuli and no increase in functional coupling between the amygdala and 
medial prefrontal cortex. These findings suggest that human narcolepsy is accompanied 
by abnormal emotional learning, and that, in line with animal data, the orexin system is 
critical for the function of the amygdala in this process.  
The neural input from the limbic system to orexin neurons is also implicated in 
pathophysiology of cataplexy, because strong, generally positive emotional stimuli are 
well known to trigger cataplexy in narcolepsy-cataplexy patients.  Local injection of 
orexin into the pedunculopontine tegmental nucleus (PPT) strongly inhibited REM-
related atonia in cats39.  These cholinergic neurons are implicated in REM-related 
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atonia40 and the same pathway is implicated in cataplexy.  Therefore, through excitatory 
influences from the limbic system, emotional stimuli might increase orexin release in 
the PPT to prevent muscle atonia in wild-type animals.  Mechanisms of action of orexin 
in the PPT/laterodorsal tegmental nucleus (LDT) will be further discussed below. In 
addition to the suppression of muscle atonia, activation of orexin neurons by the limbic 
system is likely to maintain wakefulness during emotional arousal by conveying various 
emotional stimuli to orexin neurons. 
The limbic input to orexin neurons might also be involved in the regulation of 
feeding behavior.  Some of the affective content of the perception of food is thought to 
be processed in the amygdala and limbic system41, and this information might be passed 
on to orexin neurons.  Food perception often evokes cataplexy in narcoleptic dogs 42, 
suggesting that orexin signaling is physiologically activated upon perception of food, 
and that this system is necessary to evoke proper feeding behavior including the 
maintenance of motor activity. 
Input from preoptic areas 
The preoptic area, especially the ventrolateral preoptic nucleus (VLPO) and median 
preoptic nucleus (MPO), appears to play a crucial role in NREM sleep initiation and 
maintenance.  Some neurons in the VLPO are sleep-active neurons, which fire at a rapid 
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rate during sleep and show attenuation of firing during wakefulness.  GABA and 
galanin are the primary inhibitory neurotransmitters of the VLPO43, which sends out 
multiple inhibitory projections onto the locus coeruleous (LC), tuberomammillary 
nucleus (TMN), and dorsal raphe (DR)43-44. Orexin neurons, which are strongly 
inhibited by both the GABAA agonist muscimol and the GABAB receptor agonist 
bacrofen4, 45,  are innervated by GABA-containing cells in the VLPO7-8.  This pathway 
might be important for turning off orexin neurons during sleep (Figure 2B). Selective 
disruption of GABAB receptor in orexin neurons resulted in severe fragmentation of 
sleep/wake states during both light and dark periods, suggesting GABAB receptor-
mediated regulation of orexin neurons play an important role in sleep/wake 
maintenance46. 
Input from the brainstem regions 
Orexin neurons receive inhibitory projections from the raphe nuclei47-48. An 
electrophysiological study showed that orexin neurons are also inhibited by 
noradrenalin49. As described later, serotonergic neurons in the raphe nuclei and 
noradrenergic neurons in the LC have been considered crucial for wakefulness and 
receive dense excitatory projections of orexin neurons. Thus, these observations suggest 
that orexin neurons and monoaminergic neurons constitute negative feedback loop 
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circuitry, which might play important parts in the maintenance of firing rates of each 
component within appropriate ranges (Fig. 2B).  
Factors that regulate orexin neurons 
In addition to the classical neurotransmitters, glutamate and GABA, several 
neurotransmitters/neuromodulators have been shown to influence the firing rate of 
orexin neurons. Both noradrenaline and serotonin (5HT) hyperpolarize and inhibit GFP-
expressing orexin neurons through the activation of G protein-regulated inwardly 
rectifying K+ (GIRK or Kir3) channels via 2-adrenoceptors and 5HT1A-receptors, 
respectively49-51.  The cholinergic agonist carbachol activates 27% and inhibits 6% of 
orexin neurons7, 51, whereas histamine does not have any effect on orexin neurons.  
Although orexin neurons do not express functional dopamine receptors, dopamine can 
inhibit orexin neurons by acting on 2-adrenoceptors49, 51.  Several neuropeptides, 
including cholecystokinin (CCK-8S), neurotensin, oxytocin, and vasopressin, induce 
depolarization and excitation of orexin neurons52. A synthetic surrogate ligand for an 
orphan receptor, BRS-3, also activates these neurons53.  Recently, orexin itself was 
shown to activate orexin neurons through OXR-2, suggesting a positive feed back 
mechanism that maintain orexin neuronal activity54. 
Interestingly, metabolic signals also contribute to the regulation of firing rate of 
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orexin neurons: decreasing the extracellular glucose concentration produced 
depolarization and increased the frequency of firing of orexin neurons, whereas 
increasing glucose concentration induced hyperpolarization and cessation of firing4, 55. 
Importantly, this mechanism is sufficiently sensitive to encode variations in glucose 
levels in cerebrospinal fluid reflecting those occurring physiologically between normal 
meals4, 55. These responses were shown to be mediated by tandem-pore K+ (K2P) 
channels56. In addition, hypoglycemic signals transmitted via vagal afferents and the 
nucleus of the solitary tract (NTS) were also shown to inhibit orexin neurons57-58. 
Ghrelin, a stomach-derived orexigenic peptide, activated 60% of dispersed 
orexin neurons with depolarization and an increase in firing frequency4. By contrast, 
bath-application of leptin, an anorexigenic protein hormone secreted by adipocytes, was 
found to robustly inhibit most of the orexin neurons examined, causing 
hyperpolarization and a decrease in firing rate4.  
These findings show that peripheral humoral factors that are related to energy 
metabolism influence the activity of orexin neurons. In addition, orexin expressions in 
wild-type and ob/ob mice are negatively correlated with changes in blood glucose, 
leptin, and food intake4. These observations support the idea that orexin neurons act as a 
sensor of the nutritional status1, 4, 12. 
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This suggests that nutritional depletion-induced metabolic cues activate orexin 
neurons to increase arousal, thereby reinforcing food-seeking/feeding pathways. 
Consistently, orexin neuron-ablated mice fail to exhibit this fasting-induced arousal4, 
suggesting that orexin neurons are necessary for evoking adaptive behavioral arousal 
during fasting. The mechanism that helps to ensure survival in nature clearly involves 
orexins, and might hinder attempts to treat obesity by food restriction. This might also 
explain why orexin receptor antagonists decrease food intake (see below)59.  
 
Output of orexin neurons 
Orexin-imunoreactive fibers were observed in the almost entire neuroaxis, excluding the 
cerebellum15-17.  The densest staining of fibers is found in the paraventricular nucleus of 
the thalamus, arcuate nucleus (Arc) of the hypothalamus, and most notably, 
monoaminergic nuclei in the brain stem regions, including the LC (containing 
noradrenergic neurons), raphe nuclei (containing serotonergic neurons), TMN 
(containing histaminergic neurons), and LDT/PPT (containing cholinergic neurons)16-17, 
22.  The distribution of the orexin receptor mRNA is consistent with these projection 
sites; within the brain, OXR-1 is most abundantly expressed in the LC, while OXR-2 is 
highly expressed in the TMN14.  Both regions are important for the maintenance of 
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arousal14.  The raphe nuclei, LDT/PPT, and ventral tegmental area (VTA) contain both 
OXR-1 and OXR-214, although they are expressed in distinct neuronal populations in 
each region33 (Further discuss later). These observations suggest that these 
monoaminergic regions, implicated in the regulation of wakefulness, are major effector 
sites of orexins (Figure 2). 
These monoaminergic neurons diffusely innervate the forebrain. Their 
projections are thought to be involved in the ARAS, and have been shown to play 
important roles in promoting arousal. Pontine neurons that produce acetylcholine (Ach) 
in PPT/LDT are also important for the regulation of wakefulness as well as REM sleep. 
These observations suggest that main output regions of orexin neurons are 
monoaminergic/cholinergic neurons in the brain stem. Through these connections, 
orexins exert their physiological functions.  
 
Differential Expression of Two Subtypes of Orexin Receptors 
Although it is clear that monoaminergic/cholinergic nuclei are important regions for 
orexin action, recent our observations suggest regulation of these nuclei by two 
subtypes of orexin receptors seems to be more complicated.  As discussed earlier, the 
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TMN abundantly expressed OXR-2 and the LC predominantly expressed OXR-1. In the 
LDT and PPT, expressions of both OXR-1 and OXR-2 were observed.  Likewise, the 
dorsal and median raphe nuclei (DR and MnR), both OXR-1 and OXR-2 mRNA are 
expressed.  
 Notably in the TMN, we found that most of OXR-2-positive histaminergic 
neurons also express Gad1 mRNA, suggesting that OXR-2-positive histaminergic 
neurons are also GABAergic. The majority of serotonergic neurons in the DR and MnR 
express both OXR-1 and OXR-2. We also observed expressions of  OXR-1 or OXR-2 
mRNA in GABAergic neurons in the raphe nuclei.  In the LC, all OXR-1-positive 
neurons are noradrenergic neurons.  
 In the LDT and PPT,  OXR-1 mRNA is expressed in all cholinergic neurons. 
Both OXR-1 and OXR-2  mRNA were found to be expressed in GABAergic neurons33.   
 These observations suggest that in the monoaminergic/cholinergic nuclei, two 
orexin receptors play distinct roles in regulating activity of neurons that constitutes the 




Sleep/wake regulation and orexins 
Physiological roles of orexins on sleep/wake states 
Intracerebroventricular (ICV) injection of orexin A or orexin B in rats or mice during 
the light (rest) period potently increases awake time and decreases REM and non-REM 
(NREM) sleep time60.  As discussed above, the projection pattern of orexin neurons and 
distributions of orexin receptor mRNAs suggests that main effector sites for orexin are 
monoaminergic/cholinergic neurons in the brainstem. Indeed, electrophysiological 
experiments showed that firing rates of monoaminergic cells in these nuclei are 
increased by orexins; Noradrenergic cells of the LC60-61, dopaminergic cells of the 
VTA62, serotonergic cells of the DR63-64, and histaminergic cells of the TMN 65 have all 
been shown to increase their firing rates by orexins.  The firing rates of these 
monoaminergic neurons are strongly associated with sleep/wakefulness states: they fire 
tonically during awake period, less during NREM sleep, and cease firing during REM 
sleep66. These observations suggest that increased firing of these wake-active 
monoaminergic neurons mediates arousal induced by orexins.   
 Orexins also have strong direct excitatory effects on cholinergic neurons in the 
basal forebrain, which are important for maintaining arousal and attention67-68.  In 
addition, orexin neurons project directly to the laterodorsal tegmental/pedunculopontine 
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tegmental nucleus (LDT/PPT) cholinergic neurons. Some populations of these 
cholinergic neurons are implicated in the maintenance of wakefulness and REM sleep 
(W/REM-on neurons)69, whereas other populations are implicated in desynchronization 
of cerebral cortex and muscle atonia during REM sleep (REM-on neurons)69.  Direct 
injection of orexin A into the LDT of cats results in an increased awake time and a 
decreased REM sleep time70. In addition, several reports have shown that orexin 
induces long-lasting excitation of cholinergic neurons in the LDT71. However, recent 
work also showed that orexin A inhibits cholinergic neurons in the PPT via activation of 
GABAergic local interneurons and GABAergic neurons in the substantia nigra pars 
reticulata, which send inhibitory projections to the PPT39. In fact, as discussed earlier, 
we found robust expression of OXR-1 in the cholinergic neurons, and both receptor 
expression in GABAergic neurons in these regions33. Consistently, orexin-A excites 
both cholinergic and non-cholinergic neurons of the LDT in slice preparations72. Taken 
together, these results indicate that in the LDT/PPT, orexin may activate W/REM-on 
cholinergic neurons through OX1R to facilitate wakefulness. Simultaneously, orexin 
might activate GABAergic interneurons to inhibit REM-on cholinergic neurons through 
activation of both receptors in these nuclei. Additionally, orexinergic activations of 
wake-active noradrenergic and serotonergic neurons in the LC and raphe nuclei through 
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OXR-1 and both receptors, respectively,  are likely to counteract activation of REM-on 
cholinergic neurons in the LDT/PPT during wakefulness2, 73. This is consistent with the 
fact that tricyclic antidepressants and serotonin-specific reuptake inhibitors are effective 
for treating cataplexy in narcoleptic patients. 
 
Orexin receptors in sleep and wakefulness 
It is believed that the effect of orexin on wakefulness is largely mediated by activation 
of the TMN histaminergic neurons that express OXR-265, 74.  OXR-2 KO mice and 
prepro-orexin KO mice are similarly affected by behaviorally abnormal attacks of 
NREM sleep (“sleep attacks”) 30, but OXR-2 KO mice show a lower degree of disrupted 
wakefulness compared with double receptor KO (OXR-1 - and OXR-2 -null) mice2, 32, 75.  
In particular, OXR-2 KO mice are only mildly affected by cataplexy and direct 
transitions to REM sleep from awake states30, as compared with orexin KO mice and 
double receptor KO mice12, 19 30. Orexin KO mice and double receptor KO mice have 
very similar phenotypes12,30. Thus, these observations suggest that OXR-2 plays a 
pivotal role, but OXR-1 has additional effects on sleep-wake regulation. The gating of 
REM sleep is likely to critically involve both receptors.  
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Orexinergic activity in the sleep-wake cycle 
Transgenic mice in which orexin is constitutively expressed in a diffuse, ectopic pattern 
in the brain exhibit abnormal sleep and wakefulness patterns, including fragmented 
NREM sleep in the light period and incomplete REM sleep atonia with abnormal 
myoclonic activity during REM sleep76. These results suggest that firing rate of orexin 
neurons should be decreased or ceased to maintain consolidated NREM sleep and the 
muscle atonia that accompanies REM sleep.  
Consistent with this idea, Fos expression (a marker of neuronal activity) in 
orexin neurons in rats is increased during the dark, active period in which the awake 
state is dominant77. Orexin levels in CSF peak during the dark period and decrease 
during the light period in which the sleep state is dominant78. Moreover, in vivo 
recording studies revealed changes of orexin neuronal activity across the sleep-wake 
cycle in rats or mice79-81. These studies showed that orexin neurons fire during active 
waking, decrease discharge during quiet waking, and virtually cease firing during both 
REM and NREM sleep.  
Mechanisms that underlie orexin-mediated stabilization of sleep/wakefulness states 
A reciprocal feedback loop between orexin neurons and monoaminergic neurons in the 
brainstem (including the LC and DR47, 49, 51) might maintain the activity of 
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monoaminergic neurons to stabilize wakefulness (Figure 2B). Wake-active 
monoaminergic centers are also influenced by the inhibitory projections from the POA, 
especially VLPO44.  During sleep, VLPO sleep-active neurons are thought to be 
activated by sleep substances such as adenosine82-84.  As discussed above, the sleep-
active neurons also send inhibitory projections to hypothalamic orexin neurons8, 85. 
These triangular neural circuits might be important for stability of wakefulness. 
  
Without orexin neurons, the balance between these waking-active neurons and sleep-
active neurons in the POA is likely to be delicate, and sleep and wakefulness will turn 
into the alternative mode abruptly, as observed in narcolepsy. 
Dual center model of sleep/wake regulation 
The dual center hypothesis of feeding regulation, which was proposed about fifty years 
ago, states that the ventromedial hypothalamus (VMH) is the satiety center, whereas the 
LHA is the feeding center. Although later studies have shown that the regulatory 
mechanisms of feeding are more complex (involving a number of hypothalamic regions 
including the arcuate nucleus and dorsomedial hypothalamus), satiety and feeding is a 
balancing process between two major groups of neurochemical pathways .  
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 Similarly, in sleep/wakefulness regulation, there seem to be two major groups of 
neural pathways that balance sleep and wakefulness. The effector mechanism that 
regulates cortical function is the monoaminergic/cholinergic neurons in the brainstem 
(ARAS), whose diffuse innervations to cerebral cortex play an important role in 
desynchronization of cortical neurons during wakefulness.  Orexin neurons in the LHA 
appear to be the accelerator, whereas sleep-active neurons in the preoptic area are likely 
to be the decelerator of the ARAS to regulate cortical function and sleep/wake states. 
 
 
Roles of orexins in feeding behavior and energy homeostasis 
Initially, orexins were recognized as regulators of feeding behavior because of their 
exclusive production in the LHA and their actions on food intake; ICV injection of 
orexins during the light period induces feeding behavior in rats and mice1, 59, 86-87. 
In addition, orexin mRNA expression was shown to increase during fasting1. A 
transcription factor Foxa2 is likely to mediate this phenomenon by translocating into the 
nucleus, binding to orexin promoter, and subsequently stimulating transcription of 
orexin gene in response to fasting88. 
 Genetic studies have also shown that orexins play a role in the regulation of 
energy homeostasis.  For example, orexin neuron-ablated mice display hypophagia and 
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late-onset obesity, although the extent of abnormality critically depends on the genetic 
backgrounds of the mice 21, 89. Furthermore, narcolepsy patients have a decreased 
caloric intake but an increased body mass index (BMI)90-91.  The orexin system is likely 
to positively regulate feeding as well as arousal, activity, and basal energy expenditure, 
and this might explain why narcoleptic mice and humans show increased body weight 
despite their hypophagia. 
Supporting the physiological relevance of orexin in the control of feeding, ICV 
administration of an anti-orexin antibody or an OXR-1-selective antagonist reduced 
food intake59, 92. 
OXR-2-mediated pathways might also be important for energy homeostasis93. 
Transgenic mice with ubiquitous orexin overexpression are resistant to high-fat diet-
induced obesity and insulin insensitivity by promoting energy expenditure and reducing 
consumption. Genetic and pharmacological studies indicated that OXR-2 (rather than 
OXR-1) signaling, predominantly mediates this phenotype through negative energy 
homeostasis and improved leptin sensitivity93. 
Consistent with the dense projection of orexin neurons to the Arc15, 17, 94, 
several studies have suggested that the increased food intake following orexin A 
administration  is at least partly mediated by activation of neuropeptide Y (NPY) 
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neurons in the Arc94-95.  Other events involved in orexin-induced feeding behavior 
include inhibition of proopiomelanocortin (POMC) neurons in the Arc, which are 
thought to play an important role in leptin-mediated inhibition of food intake95.  Recent 
reports also showed that infusions of orexin A into the shell of the nucleus accumbens 
(NAc) increase feeding behavior96.  In addition, infusions of the GABAA receptor 
agonist muscimol into the NAc shell strongly induced food intake and simultaneously 
increased Fos expression specifically in orexin neurons97. These findings suggest that 
reciprocal interactions between the orexin and limbic systems play a role in the 
regulation of feeding. In addition, the orexin system stimulates feeding-associated 
glucose utilization in skeletal muscle by activation of sympathetic nervous system 
through acting on the VMH98. 
As discussed above, orexin-mediated maintenance of consolidated wakefulness 
might also be important in feeding behavior, because maintenance of arousal during 
food searching and intake is essential for an animal’s survival 4, In other words, if 
energy stores are low, firing rate of orexin neurons might be increased to maintain 




Orexin system has been also implicated in many other systems, such as reward system, 
autonomic nervous system, and stress response.  In this review, we will just briefly 
mention these functions. Please refer to another review for detailed descriptions2. 
Orexin and the autonomic nervous system 
Several studies clearly showed that orexins play a role in mobilizing sympathetic 
responses. It has been demonstrated that ICV orexin injections increase blood pressure 
and heart rate, and that these effects are abolished by administration of drugs that block 
or adrenoceptors99.  Moreover, blood pressure in orexin-deficient mice is 10-15 
mmHg lower than in wild-type littermates100.  As discussed earlier, the orexin-mediated 
increase in sympathetic tone might also be involved in the mechanisms by which the 
limbic system modulates the sympathetic outflow responding to emotional stimuli36, 101. 
Orexin and the reward system 
Activation of orexin neurons was shown to be strongly linked to preferences for cues 
associated with drug and food rewards9. ICV or local VTA infusions of orexins have 
been shown to reinstate drug-seeking or food-seeking behavior in rodents3, 9.  
Conversely, the subcutaneous morphine (mu opioid receptor agonist)-induced place 
preference and hyperlocomotion observed in wild-type mice were abolished in mice that 
lacked the prepro-orexin gene10, and injections of an OXR-1 antagonist into the VTA 
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block the development of morphine-conditioned place preference10.  These observations 
suggest the strong functional interaction between orexinergic pathways and the 
dopaminergic system. In vivo administration of an OXR-1 antagonist blocks locomotor 
sensitization to cocaine and occludes cocaine-induced potentiation of excitatory currents 
in VTA dopamine neurons102.  These results suggest an important role for orexin 
signaling in the VTA in the neural plasticity associated with reward, and indicate that 
orexins also contribute to cocaine-induced psychomotor sensitization and reward-
seeking. Interestingly, some narcolepsy patients with daytime sleepiness who had been 
treated with amphetamine-like stimulants and/or sodium oxybate (gamma 
hydroxybutyrate, also known as GHB) for a long time, rarely developed drug abuse103. 
 
Therapeutic potential of drugs that target orexin receptors 
Orexin receptor antagonists 
 Orexin initially drew attention as a regulator of food intake. Therefore, several 
pharmaceutical companies developed orexin receptor antagonists to control appetite for 
obesity treatment. Indeed, an OXR-1-selective antagonist reduced food intake and 
ameliorated obesity in leptin-deficient ob/ob mice 86.  
Subsequently, because orexins have been implicated in the maintenance of 
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arousal, several companies have been exploring the possibility of using orexin receptor 
antagonists as drugs for insomnia treatment. To date, several orexin receptor antagonists 
with different pharmacological characteristics have been developed (Table 1). A first-in-
class dual orexin receptor antagonist almorexant (ACT-078573, Actelion 
Pharmaceuticals Ltd) was recently developed. It blocks both OXR-1 and OXR-2 with 
almost equimolar potency (IC50 of 16 and 15 nM, respectively). It reduces time spent in 
wake states and enables and maintains sleep in rats, dogs, and humans104-105. Recently, 
the results of a study on almorexant in 147 patients with primary insomnia were 
reported105. The drug significantly improved the primary parameter of sleep efficiency 
(time spent sleeping while confined to bed during an eight hour period at night) in a 
dose-dependent manner.  Almorexant decreased latency to sleep onset and number of 
wake bouts after sleep onset. Importantly, Actelion reports that almorexant not only 
changed these physiological sleep parameters, but also significantly improved 
subjective sleep qualities. Effective doses of almorexant did not cause any relevant 
negative effects on next-day performance (assessed by fine motor testing and mean 
reaction time), as is commonly observed with current insomnia treatments such as 
benzodiazepines which are GABA receptor modulators. In addition, it was reported that 
rats treated with administration of high doses of almorexant (300 mg/kg, p.o.), are fully 
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capable of spatial and avoidance learning106. Importantly, almorexant increases time 
spent in REM sleep, which is thought to be of key importance for our ability to store 
and process information. However, at the same the effect of REM period elongation 
might cause unwanted complications such as vivid dreaming, nightmare and sleep 
paralysis. Notably, almorexant was well tolerated with no signs of cataplexy, suggesting 
that acute, short-lived, intermittent temporary blockage of orexin receptors will not 
result in a narcolepsy-like phenotype107. 
  MK-4305 is a compound 10 with a 7-methyl substitution on the diazepane core 
with a potent dual orexin receptor antagonistic activity. This compound is also now 
under the phase III clinical trials for the treatment of primary insomnia.  
Recently, administrations of an OXR-2 selective antagonist JNJ-10397049 were 
shown to decrease the latency for persistent sleep and increased NREM sleep time more 
potently than the dual antagonist almorexant108. Administrations of an OXR-1 selective 
antagonist SB-408124 had no effect on sleep parameters. Rather, the OXR-1 antagonist 
attenuated the sleep-promoting effects of OXR-2 antagonist when simultaneously 
administered, possibly by increasing dopamine release in the prefrontal cortex. Thus, 
selective OXR-2 antagonists may offer an advantage for the treatment of insomnia. As 
discussed earlier, OXR-1 and OXR-2 are differentially distributed in the 
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monoaminergic/cholinergic regions, suggesting distinct physiological roles of these 
receptors. Further research using selective antagonists and/or each receptor KO mouse 
would be required to understand effectiveness, advantages and disadvantages of these 
compounds. 
It has been shown that orexin mediates many behaviours associated with drug 
addiction in rodents due to its effects on the VTA109.  Recent report showed that orexin-
1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-
conditioned reinforcement and the expression of amphetamine-conditioned reward, 
suggesting that OXR1-selective antagonists have the potential to be a treatment for 
individuals struggling with drug relapse and dependency110.  Although whether the 
effects of orexin are the same in humans is still unknown, it is reasonable to speculate 
that orexin receptor antagonists might be effective for treating drug addiction. This 
notion is supported by the fact that drug addiction is seldom found in narcolepsy 
patients who are treated with psychostimulants.  
OXR-1 antagonists might also be effective for panic disorders. They inhibit 




Orexin Receptor Agonists 
Because narcolepsy-cataplexy results from the absence of orexin, replacement therapy 
using orexin receptor agonists could be valuable for treating narcolepsy. These drugs 
might also be effective in other conditions of excessive daytime sleepiness. Indications 
that this might be successful come from a study demonstrating that chronic 
overproduction of orexin peptides from an ectopically expressed transgene prevented 
the development of a narcolepsy syndrome in orexin neuron-ablated (orexin/ataxin-3-
transgenic) mice 112. Acute ICV administration of orexin A also maintained wakefulness, 
suppressed sleep, and inhibited cataplectic attacks in orexin/ataxin-3 mice 112. ICV 
administration of orexin-A has stronger arousal effects in orexin/ataxin-3 transgenic 
mice than in wild-type controls112. The greater effectiveness might not result from 
increased expression of orexin receptors112. Rather, in the orexin/ataxin-3 mice, 
monoaminergic neurons in the brainstem become more sensitive to various stimuli (our 
unpublished results).  This mechanism might explain why narcoleptics cannot maintain 
long consolidated NREM sleep periods. 
 Effectiveness of ICV orexin to narcoleptic phenotype suggests orexin receptor 
agonists would be of potential value for treating narcolepsy.  However, as mentioned 
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before, chronic overexpression of orexin in an unregulated fashion results in disruption 
of NREM sleep, and therefore, it will be beneficial for therapeutically relevant orexin 
agonists to have a short half-life (<12 hr). 
 
Conclusion and perspectives 
The symptoms and the cellular and systems-level bases of narcolepsy-cataplexy 
unequivocally show that orexins and orexin receptors are important regulators of sleep 
and wakefulness and of arousal maintenance by regulating monoaminergic and 
cholinergic nuclei in the brain.  Orexin neurons receive afferents from multiple neuronal 
systems, and send excitatory signals to monoaminergic and cholinergic nuclei in the 
brainstem.  Understanding connectomics of orexin neurons more precisely might 
provide further insights into how the systems regulating emotion, energy homeostasis 
and reward interact with the mechanism that regulates sleep and wakefulness.  Further 
studies dissecting roles of each receptor in particular brain regions, by means of 
spatially-restricted deletion of each receptor gene, as well as specific regional rescue of 
each receptor to receptor KO mice, might shed light on the mechanisms of action of 




FIG. 1 Orexin and orexin receptors.  (A) Structures of various species of orexin A and 
orexin B. The topology of the two intrachain disulfide bonds of orexin A is indicated 
above the sequence. Shadows indicate amino acid identity. Mammalian orexin A 
sequences thus far identified (human, rat, mouse, pig, dog, sheep, cow) are all identical. 
(B) Orexin A and orexin B are derived from a common precursor peptide, prepro-orexin. 
The actions of orexins are mediated via two G protein-coupled receptors named orexin-
1 (OXR-1) and orexin-2 (OXR-2) receptors. OXR-1 is selective for orexin A, whereas 
OXR-2 show similar affinities for both orexin A and orexin B. OXR-1 is coupled to the 




 Fig 2. Connections of orexin neurons with other regions. Orexin neurons in the 
lateral hypothalamic area (LHA) provide a link between the limbic system, energy 
homeostasis and the brain stem nuclei. A. Major projections of orexin neurons. 
Modified from Sakurai 20072. Circles show major target sites for orexins. Included in 
these are the locus coeruleus (LC, containing noradrenaline, NA), tuberomammillary 
nucleus (TMN, containing histamine, HA), raphe nuclei (Raphe, containing 5-HT), 
ventral tegmental area (VTA, containing dopamine, DA), and 
laterodorsal/pedunclopontine tegmental nuclei (PPT/LDT, containing acetylcholine, 
Ach). Orexin neurons promote wakefulness through the monoaminergic/cholinergic 
nuclei that are wake-active. B. Schematic presentations of output and input of orexin 
neurons shown in regions of rectangle in (A). Connection between dopaminergic centers 
and orexin neurons plays to modulate the reward systems. Input from the limbic system 
might be important to regulate the activity of orexin neurons upon emotional stimuli to 
evoke emotional arousal or fear-related responses. Sleep-active neurons in the POA 
send inhibitory influences to monoaminergic/cholinergic neurons and orexin neurons. 
Orexin neurons send both direct excitatory input to cholinergic neurons in the LDT/PPT 
and indirect inhibitory input to these cells through GABAergic local interneurons and 
GABAergic neurons in the substantia nigra pars reticulata39.  Noradrenergic neurons in 
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the LC and serotonergic neurons in the RN also send inhibitory influences to these 
cholinergic neurons.  Blood glucose levels also affect the activity of orexin neurons 
through fluctuations of glucose levels in the CSF and vagal afferent. 
NAc, nucleus accumbens; PVH, paraventricular hypothalamic nucleus; TMN, 
tuberomammilary nucleus; LHA, lateral hypothalamic area; DMH, dorsomedial 
hypothalamus; ARC, arcuate nucleus; VTA, ventral tegmental area; SN, substantia 
nigra; SCN, suprachiasmatic nucleus; RN, raphe nucleus; LC, locus coeruleus; PPT, 
pedunculopontine tegmental nucleus; LDT, laterodorsal tegmental nucleus 
 
Fig. 3. Schematic illustration of presumed pathways underlying orexin actions on 
NREM and REM sleep33. Orexins activate histaminergic (His)/GABAergic (GA), 
serotonergic (5HT), noradrenergic (NA), and cholinergic (ACh) neurons, as well as 
GABAergic putative interneurons, in wake-promoting nuclei, including the TMN, 
DR/MnR, LDT/PPT, and LC. These neurons differentially express OXR-1 and/or OXR-
2, and regulate wakefulness/NREM sleep and NREM/REM sleep transitions. OXR-1 
and OXR-2 may be expressed in the same populations of GABAergic neurons, as 
shown in the figure, or may be expressed in distinct populations of these neurons in 
each area. Wake/REM-on cholinergic neurons (ACh/W) are likely to suppress NREM 
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sleep but REM-on cholinergic neurons (ACh/R) are likely to induce REM sleep. Wake-
active serotonergic and noradrenergic neurons in the DR/MnR and LC, respectively, 
counteract activation of REM-on cholinergic neurons in the LDT/PPT, as well as REM-
on neurons in the brainstem reticular formation2,71. Previous reports have suggested 
contributions of GABAergic interneurons inhibiting PPT cholinergic and raphe 





  Affinity  Units Ref 
 Compound OXR-1 OXR-2   
DORA ACT-078573 (almorexant) 7.9 (human), 7.8 
(rat) 
8.1 (human), 7.8 
(rat) 
pIC50 104 
DORA MK-4305 9.26 9.46 pKi 113 
OXR-1 
SORA 
SB-410220 7.7 nd pKi 114 
OXR-1 
SORA 
SB-334867 7.2 nd pKi 114 
OXR-1 
SORA 
SB-408124 7 nd pKi 114 
OXR-1 
SORA 
[3H]SB-674042 8.3 nd pKd 114 
OXR-1 
SORA 
SB-410220 8.1 6.3 pKb 114 
OXR-1 
SORA 
SB-334867 7.4 5.7 pKb 115 
OXR-1 
SORA 
SB-408124 7.7 5.9 pKb 114 
OXR-1 
SORA 











5.3 – 5.8 8.0 – 8.6 pKi 116 
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signal sequence GKR GRR
Amygdala
VTA
NTS
Dorsal Striatum
NAc
LHADMH
PVH
ARC
RN
SN
PPT
TMN
LDT
LC
Dopamine
Serotonin
Histamine
Acetylcholine
Noradrenaline
Orexin
POA
SCN
A
B
vagal input
Glucose
orexin
